Welcome!

News Feed Item

Stakeholder Perspectives: Innovation within the Biopharma Industry

NEW YORK, March 3, 2014 /PRNewswire/ -- New Reportlinker.com announces that a new market research report is available in its catalogue: Stakeholder Perspectives: Innovation within the Biopharma Industry

http://www.reportlinker.com/p02027811/Stakeholder-Perspectives-Innovation-within-the-Biopharma-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Discovery_and_Development

What does innovation mean within the biopharma industry? How much you spend on R&D? How many products you bring to market? How many New Molecular Entities (NME) you have in research?

Within the biopharma industry, R&D output is at odds with R&D investment. Between 1950 and 2010, the number of new molecules (including both biologics and small molecules) brought to market by the biopharma industry, per billion dollars of R&D expenditure, fell by a factor of 100 in inflation adjusted terms. Innovation, it seems, is getting increasingly expensive while the prospect of blockbuster income to pay for it is getting rarer. Something has to change.

So...what are the issues we need to consider?

- New molecular entity (NME) output is not an accurate reflection of the state of innovation: new ways of measuring innovation within the biopharma industry are needed. Current methods of measuring NME output from either the FDA or EMA provide only a snapshot of what regulatory agencies deem approvable. The industry needs to move beyond NME output as a measure of innovation, taking into account provider, purchaser and user metrics including pipeline activity, clinical success, regulatory approval, patient access, satisfaction of unmet need and overall value to society;

- Collaboration is critical to success: Industry must leverage the experience, skills and insights from a diverse range of stakeholders such as physicians, patients and payers – this is critical to the future of innovation. But collaboration needs to be smart. Biopharma companies must collaborate only when the expected outcome adds value to society, contributes to better patient outcomes and supports commercial goals;

- Companies need to be brave: constantly mining a 'comfort zone' of known approaches leads to complacency and limits innovation. While many believe that all of the 'low hanging fruit' have been taken there is another perspective: that there is plenty of fruit left on the tree and companies just need the bravery and vision to look for them.

This FirstView advisory report – the first in a major new series – provides everyone interested in the dynamics of biopharma innovation with a robust understanding of the issues, opinions and insights that are shaping the current environment, and the events that could lead to a change in the future. Every aspect of the report is informed by expert insight gathered from 60-minute interviews with 16 key opinion leaders (KOLs), payers and senior industry executives from leading companies from across Europe and the US.

Experts share their insights on...

- The impact of innovation within biotechnology over the last 15-20 years- A view of what a world without biologics would have looked like
- The pros and cons of biological therapies
- Where biologics have been best received and where there is still resistance
- The role that industry played, and needs to play, within the 'innovation ecosystem'
- The important and growing roles of key stakeholder groups
- Attitudes toward innovation within industry
- New technologies and innovations that are exciting industry at the moment, and hypotheses about the future of innovation and roles in driving it forward
- This report tackles the pressing innovation issues and questions

What does biopharma innovation mean?

- Where is innovation coming from?
- How can the lessons of the last few decades be used to guide future biopharma innovation?
- What will be the future trends in biopharma innovation?
- How has biopharma innovation been measured in the past, and do new ways of measuring innovation need to be developed?
- What must biopharma companies focus on in order to remain competitive and deliver innovation that is truly valued by society?
- Which companies are currently viewed as being leaders of innovation within the pharmaceutical industry?
- What disruptive technologies and market dynamics are likely to impact the rate of innovation within the biopharma industry?
- What do KOLs, payers and industry stakeholders view as critical for biopharma companies to focus on in order to maintain shareholder returns and deliver customer value?

Whether you work in big pharma, a drug discovery company, patient advocacy group or regulatory body, this report Stakeholder Perspectives: Innovation within the Biopharma Industry provides a thought provoking assessment of how we can better cost-effectively develop and bring biopharmaceuticals to the market in a timely manner.

Report Benefits

- Understand and evaluate the current status of innovation within the biopharma industry, including the key drivers and resistors of innovation

- Get up to speed with current thinking on how innovation is measured within the biopharma industry

- Know what potential changes need to be made in terms of how innovation will be assessed in the future

- Understand clinical, payer and industry opinions of current and future market dynamics

- Appreciate what the critical opportunities biopharma companies should be investing in and how these opportunities can be realised

Selected Quotes from the Report

'Innovation [within pharma] is a lot like a fine Swiss watch. There are multiple moving parts but if you take one part out, the watch stops. So every part in that watch is absolutely critical to the functioning of that watch in the same way that every key stakeholder group within the innovation ecosystem has a critical role. Whether it be a payer, a physician, a company, a policy maker, a scientist, etc. They all have a role to play and if they stop playing that role, the system falls over.' Former Head of Innovation, Eli Lilly.

'Collaboration is your key for survival for the future. You cannot always count on the old model of finding solutions inside your own company.' Global Head of External Innovation & Strategic Partnerships, Roche.

'If we had a shorter, faster, more efficient regulatory system, then the cost [and time taken] to complete clinical trials would go down. I think we need to re-think how it could be smarter, more efficient. At the moment, the regulatory system is set up to benefit big pharma, not smaller companies.' Scientific Advisor, Innogen Institute.

'My view is that biopharma companies need to be more receptive to new models of innovation, and that includes more collaborations, more discussions, sharing of data. I'm not a big believer of we [the biopharma industry] are better than everyone else and we know better, so I think that being open to the environment is really important.' Head of Innovation at Merck Serono.

'Do we have a secret sauce [when it comes to innovation]? I don't know. I think it's the willingness to take a little bit of risk in that space. I think understanding that as good as we have been in the past, it wasn't enough. We knew that that landscape was clearly changing and under some great leadership, we were able to move into a completely new system. Good people like to follow good leaders so that's certainly a part of it.' VP Strategy & Operations, Janssen R&D.

'My personal opinion is that the time of the very, very large pharma companies is maybe already over. They're not dynamic enough to react very quickly to changing and dynamic patient needs, so smaller conglomerates of people who throw their expertise into one bucket and do that quickly might win over large pharma companies.' Senior Manager, Boehringer Ingelheim.

Experts interviewed for this report

This report benefits from the considered insight of leading clinicians, payers and senior industry experts. These include:

KOL's with relevant clinical, regulatory, scientific and commercial experience, scientific publications, involvement in clinical trials and their record of presenting at high profile international conferences.

Payers with relevant (and recent) experience of deciding on the reimbursement of expensive biological therapies in areas such as oncology, inflammatory conditions, orphan diseases and infectious diseases.

Senior industry executives with current (or recent) experience in innovation, strategy, business development, licensing, competitive intelligence and long-term planning.

Their names have been kept confidential to provide contributors with a secure forum in which they could share their candid opinions and views.

Key Opinion Leaders

Rheumatologist, UK

Rheumatologist, Germany

Rheumatologist, US

Oncologist, US

Payers

Director, Managed Care Organization

Former Pharmacy Director, Harvard Pilgrim Health

Director, Health Insurance (Germany)

Head of Medicines Management, CCG (UK)

Industry Experts

Former Head of Innovation at Eli Lilly

Senior Manager, Boehringer Ingelheim

Head of Innovation, Merck Serono

Scientific Advisor, Innogen Institute

VP Strategy & Operations, Janssen R&D

Global Head, Innovation & Partnerships, Roche

Two senior executives from a large EU-based biotech firm

Who should read this report, and why?

FirstView's Stakeholder Perspectives: Innovation within the Biopharma Industry is a 'must read' for industry executives working in the areas of innovation strategy, business development & licensing, competitive intelligence, long-term planning, market access, R&D, partnering & alliance management, and emerging markets. Each stakeholder group will be able to use the insight delivered in the report to:

- Review aims, objectives and goals of current innovation strategy, and what (on the basis of the way the market is evolving) will be the critical success factors for future success;

- Reassess business development and licensing needs, aims and objectives to ensure that all future deals are accretive in terms of their ability to deliver innovative products to the market;

- Review external competitor strategies with a view to ensuring internal stakeholders are kept up to speed with market and competitive developments;

- Perform internal scenario analyses of various opportunities (e.g. gene therapy, regenerative medicine and technology opportunities) to see what will be needed to leverage the opportunity, and to understand what potential future business models will be needed;

- Review relationships with payers, asking the question 'are we providing the right data to payers for our innovative products'?

- Review current clinical trial strategies to improve the effectiveness of clinical trials, making them faster, smarter and cheaper, and review regulatory strategies based on increased regulatory hurdles;

- Get a better understanding of what critical attributes are needed in partners when assessing collaborations and joint ventures;

- Engage in portfolio optimisation work in emerging markets to ensure that needs of the market are being addressed by current portfolio; if not, review opportunities to in-license, partner, divest assets.

About FirstView Reports

FirstWord's FirstView Stakeholder Perspectives: Innovation within the Biopharma Industry is the first of a new series of authoritative analyses that focus on the drivers and resistors of innovation within the biopharma industry.

Innovation is the life blood of the industry, yet the cost of developing and bringing new products to market is spiralling. The series will forensically examine and answer fundamental questions such as:

- As the market moves away from blockbusters to 'niche-busters', how can industry and regulators bring new products to market that are not only safe and effective, but also affordable?

- Is the current clinical trials system still fit for purpose, or does industry and the regulators need to develop innovative, more efficient ways of establishing the clinical utility of new medicines?

- Are the advances in personalised medicine already witnessed only the tip of the iceberg, or have we seen all there is to offer in the field of stratified medicine?

- Are biosimilars set to take the market by storm and deliver on the promise of high quality, affordable biologics for all, or will the sector crumble under the weight of its own expectations?

- 'Beyond the Pill.' Do you have a strategy? Do you need one? And how influential will payers be when it comes to the impact of 'beyond the pill' solutions on biopharma revenues?

The pharmaceutical industry is on the verge of significant change. Old biopharma business models are under significant stress, and things need to change. Make sure you understand the potential strategic implications of these upcoming changes with FirstWord's FirstView Reports!

1.Executive summary

2.Research methodology, aims and objectives

3.Innovation within the biopharma industry

3.1.A review and analysis of the defining characteristics of today's biopharma industry, and how they are effecting innovation

3.2.The measurement and benchmarking of innovation within the biopharma industry, and some views on the key drivers and resistors of innovation

4.Key stakeholders in the innovation ecosystem

4.1.Who they are, and what their roles must be in order to drive innovation

4.2.Future perspectives on how each key stakeholder group must learn to work together more closely

5.Opportunities for biopharma companies, both now and in the future

5.1.A review and analysis of some of the key opportunities biopharma companies should be investing in to drive future growth, including 'beyond the pill' strategies, biosimilars, cancer immunotherapy, gene therapy, regenerative medicine, personalised medicine and networks.

6.A scenario-based analysis of potential biopharma futures

6.1An overview of scenarios, and how they can be used to analyse potential future market dynamics

6.2.The critical scenario drives of this report, and how they were devised

6.3.Four potential scenarios, with a robust review of each scenario in terms of its potential implications to the key stakeholders within the innovation ecosystem

6.4.Expert views and insight on the scenarios, and what it could mean for biopharma companies.

7.Concluding remarks

To order this report: Stakeholder Perspectives: Innovation within the Biopharma Industry

http://www.reportlinker.com/p02027811/Stakeholder-Perspectives-Innovation-within-the-Biopharma-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Discovery_and_Development

Contact Clare:
[email protected]
US: (339)-368-6001
Intl: +1-339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
SYS-CON Events announced today that Juniper Networks (NYSE: JNPR), an industry leader in automated, scalable and secure networks, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Juniper Networks challenges the status quo with products, solutions and services that transform the economics of networking. The company co-innovates with customers and partners to deliver automated, scalable and secure network...
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm. In his Day 3 Keynote at 20th Cloud Expo, Chris Brown, a Solutions Marketing Manager at Nutanix, will explore t...
SYS-CON Events announced today that SoftLayer, an IBM Company, has been named “Gold Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2016, at the Javits Center in New York, New York. SoftLayer, an IBM Company, provides cloud infrastructure as a service from a growing number of data centers and network points of presence around the world. SoftLayer’s customers range from Web startups to global enterprises.
Some people worry that OpenStack is more flash then substance; however, for many customers this could not be farther from the truth. No other technology equalizes the playing field between vendors while giving your internal teams better access than ever to infrastructure when they need it. In his session at 20th Cloud Expo, Chris Brown, a Solutions Marketing Manager at Nutanix, will talk through some real-world OpenStack deployments and look into the ways this can benefit customers of all sizes....
Deep learning has been very successful in social sciences and specially areas where there is a lot of data. Trading is another field that can be viewed as social science with a lot of data. With the advent of Deep Learning and Big Data technologies for efficient computation, we are finally able to use the same methods in investment management as we would in face recognition or in making chat-bots. In his session at 20th Cloud Expo, Gaurav Chakravorty, co-founder and Head of Strategy Development ...
SYS-CON Events announced today that Linux Academy, the foremost online Linux and cloud training platform and community, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Linux Academy was founded on the belief that providing high-quality, in-depth training should be available at an affordable price. Industry leaders in quality training, provided services, and student certification passes, its goal is to c...
SYS-CON Events announced today that CA Technologies has been named “Platinum Sponsor” of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY, and the 21st International Cloud Expo®, which will take place October 31-November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. CA Technologies helps customers succeed in a future where every business – from apparel to energy – is being rewritten by software. From ...
Interoute has announced the integration of its Global Cloud Infrastructure platform with Rancher Labs’ container management platform, Rancher. This approach enables enterprises to accelerate their digital transformation and infrastructure investments. Matthew Finnie, Interoute CTO commented “Enterprises developing and building apps in the cloud and those on a path to Digital Transformation need Digital ICT Infrastructure that allows them to build, test and deploy faster than ever before. The int...
In his session at @ThingsExpo, Eric Lachapelle, CEO of the Professional Evaluation and Certification Board (PECB), will provide an overview of various initiatives to certifiy the security of connected devices and future trends in ensuring public trust of IoT. Eric Lachapelle is the Chief Executive Officer of the Professional Evaluation and Certification Board (PECB), an international certification body. His role is to help companies and individuals to achieve professional, accredited and worldw...
What if you could build a web application that could support true web-scale traffic without having to ever provision or manage a single server? Sounds magical, and it is! In his session at 20th Cloud Expo, Chris Munns, Senior Developer Advocate for Serverless Applications at Amazon Web Services, will show how to build a serverless website that scales automatically using services like AWS Lambda, Amazon API Gateway, and Amazon S3. We will review several frameworks that can help you build serverle...
SYS-CON Events announced today that Loom Systems will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Founded in 2015, Loom Systems delivers an advanced AI solution to predict and prevent problems in the digital business. Loom stands alone in the industry as an AI analysis platform requiring no prior math knowledge from operators, leveraging the existing staff to succeed in the digital era. With offices in S...
SYS-CON Events announced today that Interoute, owner-operator of one of Europe's largest networks and a global cloud services platform, has been named “Bronze Sponsor” of SYS-CON's 20th Cloud Expo, which will take place on June 6-8, 2017 at the Javits Center in New York, New York. Interoute is the owner-operator of one of Europe's largest networks and a global cloud services platform which encompasses 12 data centers, 14 virtual data centers and 31 colocation centers, with connections to 195 add...
The Software Defined Data Center (SDDC), which enables organizations to seamlessly run in a hybrid cloud model (public + private cloud), is here to stay. IDC estimates that the software-defined networking market will be valued at $3.7 billion by 2016. Security is a key component and benefit of the SDDC, and offers an opportunity to build security 'from the ground up' and weave it into the environment from day one. In his session at 16th Cloud Expo, Reuven Harrison, CTO and Co-Founder of Tufin, ...
SYS-CON Events announced today that T-Mobile will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. As America's Un-carrier, T-Mobile US, Inc., is redefining the way consumers and businesses buy wireless services through leading product and service innovation. The Company's advanced nationwide 4G LTE network delivers outstanding wireless experiences to 67.4 million customers who are unwilling to compromise on ...
SYS-CON Events announced today that HTBase will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. HTBase (Gartner 2016 Cool Vendor) delivers a Composable IT infrastructure solution architected for agility and increased efficiency. It turns compute, storage, and fabric into fluid pools of resources that are easily composed and re-composed to meet each application’s needs. With HTBase, companies can quickly prov...